pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLCpulmo-2811Research ArticleНОВОЕ О ЛЕКАРСТВЕННЫХ ПРЕПАРАТАХНовые данные подтверждают – Форадил (формотерола фумарат) улучшает качество жизни больных ХОБЛNew data confirm that Foradil (formoterol fumarate) improves quality of life of COPD patientsРедакционнаястатьяEditorialArticle
Novartis Pharma AGRussian Federation20013006200102123124Copyright © Редакционная с., 20012001Редакционная с.Editorial a.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/2811
.
.
ReferencesPoster 498: Formoterol dry powder improves the quality of life in patients with COPD whereas the effect of ipratropium bromide is similar to placebo. A.P.M.Greefhorst1, R.Dahl2, D.Nowak3, V. Nonikov4, C.Colacchio5, A.M.Byrne5; 1. Streekziekenhuis Midden Twente, Hengelo, The Netherlands; 2. Aarhus Kommunehospital, Denmark; 3. Klinika Pneumonologii I Elergologii, Lodz, Poland; 4. Central Clinical Hospital, Moscow, Russia; 5. Novartis Horsham Research Centre, United Kingdom.Poster 498: Formoterol dry powder improves the quality of life in patients with COPD whereas the effect of ipratropium bromide is similar to placebo. A.P.M.Greefhorst1, R.Dahl2, D.Nowak3, V. Nonikov4, C.Colacchio5, A.M.Byrne5; 1. Streekziekenhuis Midden Twente, Hengelo, The Netherlands; 2. Aarhus Kommunehospital, Denmark; 3. Klinika Pneumonologii I Elergologii, Lodz, Poland; 4. Central Clinical Hospital, Moscow, Russia; 5. Novartis Horsham Research Centre, United Kingdom.Poster 499: Onset of action of inhaled formoterol compared to ipratropium bromide in patients with COPD. R.Dahl*, A.P.M.Greefhorstf, D.Nowakf, V.Nonikov, A.Byrne** and the Novartis Study Group on COPD. *Aarhus Kommunehospital, DK; fStreekziekenhuis Midden Twente, Hengelo, NL; fKlinika Pneumonologii I Elergologii, Lodz, PL; Central Clinical Hospital, Moscow, RUS; and **The Novartis Horsham Research Centre, GB.Poster 499: Onset of action of inhaled formoterol compared to ipratropium bromide in patients with COPD. R.Dahl*, A.P.M.Greefhorstf, D.Nowakf, V.Nonikov, A.Byrne** and the Novartis Study Group on COPD. *Aarhus Kommunehospital, DK; fStreekziekenhuis Midden Twente, Hengelo, NL; fKlinika Pneumonologii I Elergologii, Lodz, PL; Central Clinical Hospital, Moscow, RUS; and **The Novartis Horsham Research Centre, GB.Poster 497: The cardiac safety profile of formoterol dry powder is similar to placebo in patients with COPD R.Dahl1, P.Kristufek2, A.P.M.Greefhorst3, T.R.Amgott4, G.Della Cioppa5, M.H.Thomson5; ‘Aarhus Kommunehospital, Denmark; 2National ТВ and Respiratory Disease Institute, Bratislava, Slovak Republic; 3Streekziekenhuis Midden Twente, Hengelo, The Netherlands; 4Pulmonary Associates, PA, Phoenix, Arizona; 5Novartis Horsham Research Centre, United Kingdom.Poster 497: The cardiac safety profile of formoterol dry powder is similar to placebo in patients with COPD R.Dahl1, P.Kristufek2, A.P.M.Greefhorst3, T.R.Amgott4, G.Della Cioppa5, M.H.Thomson5; ‘Aarhus Kommunehospital, Denmark; 2National ТВ and Respiratory Disease Institute, Bratislava, Slovak Republic; 3Streekziekenhuis Midden Twente, Hengelo, The Netherlands; 4Pulmonary Associates, PA, Phoenix, Arizona; 5Novartis Horsham Research Centre, United Kingdom.1999 World Health Report. World Health Organization, 1999.1999 World Health Report. World Health Organization, 1999.
The authors declare that there are no conflicts of interest present.